Clinical Trial Update: Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating continuous or intermittent dosing of pyrotinib in HER2-positive advanced breast cancer, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Wenjin Yin | Conditions: Advanced Breast Cancer | Phase 2 | Status: RECRUITING